Does Exscientia PLC Sponsored ADR (EXAI) Have the Potential to Rally 104.18% as Wall Street Analysts Expect?Zacks Investment Research • 10/30/23
Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ESMO 2023Business Wire • 10/16/23
Wall Street Analysts Predict a 99.07% Upside in Exscientia PLC Sponsored ADR (EXAI): Here's What You Should KnowZacks Investment Research • 10/13/23
Exscientia PLC Sponsored ADR (EXAI) Stock Jumps 13.5%: Will It Continue to Soar?Zacks Investment Research • 10/12/23
Down -33.28% in 4 Weeks, Here's Why Exscientia PLC Sponsored ADR (EXAI) Looks Ripe for a TurnaroundZacks Investment Research • 09/21/23
Exscientia's stock rockets toward a record gain after AI-driven drug discovery collaboration with Germany's Merck KGaAMarket Watch • 09/20/23
Exscientia Announces AI Drug Discovery Collaboration with Merck KGaA, Darmstadt, GermanyBusiness Wire • 09/20/23
Exscientia to Report Second Quarter 2023 Financial Results on August 10, 2023Business Wire • 08/03/23